GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bluejay Diagnostics Inc (NAS:BJDX) » Definitions » EV-to-EBIT

Bluejay Diagnostics (Bluejay Diagnostics) EV-to-EBIT : 0.04 (As of May. 06, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Bluejay Diagnostics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Bluejay Diagnostics's Enterprise Value is $-0.39 Mil. Bluejay Diagnostics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-10.31 Mil. Therefore, Bluejay Diagnostics's EV-to-EBIT for today is 0.04.

The historical rank and industry rank for Bluejay Diagnostics's EV-to-EBIT or its related term are showing as below:

BJDX' s EV-to-EBIT Range Over the Past 10 Years
Min: -1.77   Med: 0.07   Max: 0.64
Current: 0.04

During the past 5 years, the highest EV-to-EBIT of Bluejay Diagnostics was 0.64. The lowest was -1.77. And the median was 0.07.

BJDX's EV-to-EBIT is ranked better than
98.26% of 460 companies
in the Medical Devices & Instruments industry
Industry Median: 20.355 vs BJDX: 0.04

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Bluejay Diagnostics's Enterprise Value for the quarter that ended in Dec. 2023 was $-0.34 Mil. Bluejay Diagnostics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-10.31 Mil. Bluejay Diagnostics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 2,995.50%.


Bluejay Diagnostics EV-to-EBIT Historical Data

The historical data trend for Bluejay Diagnostics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bluejay Diagnostics EV-to-EBIT Chart

Bluejay Diagnostics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
- - -10.39 0.21 0.03

Bluejay Diagnostics Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 -0.21 -0.06 -0.07 0.03

Competitive Comparison of Bluejay Diagnostics's EV-to-EBIT

For the Medical Devices subindustry, Bluejay Diagnostics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bluejay Diagnostics's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bluejay Diagnostics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Bluejay Diagnostics's EV-to-EBIT falls into.



Bluejay Diagnostics EV-to-EBIT Calculation

Bluejay Diagnostics's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-0.385/-10.312
=0.04

Bluejay Diagnostics's current Enterprise Value is $-0.39 Mil.
Bluejay Diagnostics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bluejay Diagnostics  (NAS:BJDX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Bluejay Diagnostics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-10.312/-0.3442492
=2,995.50 %

Bluejay Diagnostics's Enterprise Value for the quarter that ended in Dec. 2023 was $-0.34 Mil.
Bluejay Diagnostics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bluejay Diagnostics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Bluejay Diagnostics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Bluejay Diagnostics (Bluejay Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
360 Massachusetts Avenue, Suite 203, Acton, MA, USA, 01720
Bluejay Diagnostics Inc is a medical diagnostics company. It is engaged in developing, manufacturing, and marketing of clinical diagnostic products that improve the quality of medical diagnoses. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings. The company is a provider of rapid tests for infectious, inflammatory, and metabolic diseases by the Symphony platform.
Executives
Svetlana Dey director, 10 percent owner 360 MASSACHUSETTS AVE, SUITE 203, ACTON MA 01720
Indranil Dey director, 10 percent owner, officer: Chief Technology Officer 360 MASSACHUSETTS AVENUW, SUITE 203, ACTON MA 0170
Frances P Scally officer: CFO 66 MELANIE LANE, SYOSSET NY 11791
Jason Cook officer: Chief Technology Officer 360 MASSACHUSETTS AVE, SUITE 203, ACTON MA 01720
Kenneth R Fisher officer: Chief Financial Officer 67 PROSPECT STREET, PEABODY MA 01960
Douglas Clark Wurth director, 10 percent owner 4265 SAN FELIPE, SUITE 603, HOUSTON TX 77027
Gordon Winston Kinder officer: Chief Financial Officer 360 MASSACHUSETTS AVENUE, SUITE 203, ACTON MA 01720
Gary G Gemignani director C/O IASO PHARMA INC., 12707 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Fred S Zeidman director 109 NORTH POST OAK LANE, SUITE 422, HOUSTON TX 77024
Donald R Chase director 39 TIMBER RIDGE RD., WEST SPRINGFIELD MA 01089